Down But Not Out: The Pharma Policies That Still May Ride With Senate Finance’s PBM Reform

A new biosimilar payment boost, a true, but more limited patient-directed pass-through rebate plan, and product hopping legislation are among the more than two-dozen amendments that could be added to the Senate Finance Committee’s PBM reform package.